According to DelveInsight’s latest evaluation, the global Tourette syndrome treatment pipeline features more than 6 prominent companies actively advancing over 6 investigational therapies. The comprehensive assessment covers ongoing clinical trials, therapeutic candidates, mechanisms of action, administration routes, and notable developmental milestones.
The Tourette Syndrome Pipeline Report provides an in-depth profile of each drug candidate, encompassing its mechanism of action, clinical trial data, NDA approval status where applicable, and key product development activities—including technological innovations, strategic collaborations, licensing agreements, mergers and acquisitions, funding activities, regulatory designations, and other pertinent product details.
To learn more about the latest advances shaping the Tourette Syndrome treatment pipeline, access the full report here: https://www.delveinsight.com/sample-request/tourette-syndrome-pipeline-insight?utm_source=pgnw&utm_medium=pressrelease&utm_campaign=kkpr
Key Highlights from the Tourette Syndrome Pipeline Report
- DelveInsight’s pipeline analysis reveals a dynamic and actively evolving landscape, with 6+ companies engaged in developing 6+ investigational treatment candidates.
- Leading organizations driving Tourette syndrome drug development include Emalex Biosciences, Noema Pharma, Asarina Pharma, Teva Pharmaceutical, SciSparc, EuMentis Therapeutics, Synendos Therapeutics, and others.
- Noteworthy pipeline therapies progressing through various stages of clinical development include TEV-50717, ABX-1431, Sepranolone, SD-809, Ecopipam, Valbenazine, Aripiprazole Oral Solution, NBI-98854, AZD5213, Pramipexole Immediate Release (IR), Aripiprazole, Dronabinol and Palmitoylethanolamide, among others.
- In June , Asarina Pharma initiated a Phase 2a clinical study for Sepranolone—an open-label, randomized, multicenter, parallel-design trial enrolling adolescents and adult patients with Tourette syndrome. The study was designed to evaluate Sepranolone’s therapeutic potential in reducing the severity and frequency of tics.
- In July , Emalex Biosciences Inc. launched a Phase 3 multicenter trial for Ecopipam Hydrochloride, assessing the sustained efficacy, safety, and tolerability of ecopipam tablets in children, adolescents, and adults with Tourette’s Disorder (TD). The trial design incorporates an open-label treatment period followed by a double-blind, placebo-controlled, randomized withdrawal phase.
Tourette Syndrome: Disease Overview
Tourette syndrome (TS) is an inherited neurological movement disorder defined by recurrent, involuntary motor and vocal tics. Symptoms typically manifest as uncontrollable movements of the extremities, shoulders, and face, often accompanied by involuntary vocalizations, sounds, and in some cases, inappropriate language.
For deeper insights into the evolving Tourette Syndrome treatment pipeline, request a sample report here: https://www.delveinsight.com/sample-request/tourette-syndrome-pipeline-insight?utm_source=pgnw&utm_medium=pressrelease&utm_campaign=kkpr
Featured Emerging Drug Profiles
- Ecopipam – Developed by Emalex Biosciences
- SCI-110 – Developed by SciSparc
Tourette Syndrome Pipeline Therapeutic Assessment
Approximately 6+ key companies are currently pursuing therapeutic candidates for Tourette syndrome. Among them, Emalex Biosciences has advanced its drug candidate to the most advanced stage, with its therapy currently in Phase III clinical development.
To explore the latest clinical trial updates and emerging Tourette Syndrome medications, request a sample here: https://www.delveinsight.com/sample-request/tourette-syndrome-pipeline-insight?utm_source=pgnw&utm_medium=pressrelease&utm_campaign=kkpr
Tourette Syndrome Investigational Drugs and Their Developers
| Therapeutic Candidate | Company |
| TEV-50717 | Teva Pharmaceutical Inc. |
| ABX-1431 | Abide Therapeutics |
| Sepranolone | Asarina Pharma |
| SD-809 | Auspex Pharmaceuticals Inc. |
| Ecopipam | Emalex Biosciences Inc. |
Pipeline Therapeutic Assessment Framework
- Classification by Development Stage and Product Type
- Classification by Route of Administration
- Stage-Wise Breakdown by Route of Administration
- Classification by Molecule Type
- Stage-Wise Breakdown by Molecule Type
Prominent Companies in the Tourette Syndrome Therapeutics Market
Key industry players shaping the Tourette syndrome treatment landscape include Emalex Biosciences, Noema Pharma, Asarina Pharma, Teva Pharmaceutical, SciSparc, EuMentis Therapeutics, Synendos Therapeutics, and several others.
For comprehensive insights into unmet medical needs and expert analyst perspectives on the Tourette Syndrome pipeline, access the report here: https://www.delveinsight.com/sample-request/tourette-syndrome-pipeline-insight?utm_source=pgnw&utm_medium=pressrelease&utm_campaign=kkpr
Scope of the Tourette Syndrome Pipeline Report
- Geographic Coverage: Global
- Key Companies Profiled: Emalex Biosciences, Noema Pharma, Asarina Pharma, Teva Pharmaceutical, SciSparc, EuMentis Therapeutics, Synendos Therapeutics, and others
- Key Pipeline Therapies Analyzed: TEV-50717, ABX-1431, Sepranolone, SD-809, Ecopipam, Valbenazine, Aripiprazole Oral Solution, NBI-98854, AZD5213, Pramipexole Immediate Release (IR), Aripiprazole, Dronabinol and Palmitoylethanolamide, and others
- Report Segmentation: Product Type, Molecule Type, Route of Administration
For inquiries related to Tourette Syndrome mergers and acquisitions, licensing activities, and strategic developments, visit: https://www.delveinsight.com/sample-request/tourette-syndrome-pipeline-insight?utm_source=pgnw&utm_medium=pressrelease&utm_campaign=kkpr
Table of Contents
- Introduction
- Executive Summary
- Tourette Syndrome: Disease Overview
- Pipeline Therapeutics
- Therapeutic Assessment
- Tourette Syndrome – DelveInsight’s Analytical Perspective
- Late-Stage Candidates (Phase III)
- Drug Profile: Company Details
- Detailed Drug Profiles (continued in full report)
- Mid-Stage Candidates (Phase II)
- Ecopipam: Emalex Biosciences
- Detailed Drug Profiles (continued in full report)
- Mid-Stage Candidates (Phase II)
- SCI-110: SciSparc
- Detailed Drug Profiles (continued in full report)
- Pre-Clinical and Discovery-Stage Candidates
- Drug Profile: Company Details
- Detailed Drug Profiles (continued in full report)
- Inactive and Discontinued Products
- Tourette Syndrome: Key Companies
- Tourette Syndrome: Key Products
- Tourette Syndrome: Unmet Medical Needs
- Tourette Syndrome: Market Drivers and Barriers
- Tourette Syndrome: Future Outlook and Conclusions
- Tourette Syndrome: Expert Analyst Commentary
- Tourette Syndrome: Key Company Profiles
- Appendix
About DelveInsight
DelveInsight is a leading business consulting and market research firm specializing in the healthcare sector. The company delivers expert advisory services across key domains, including Research & Development, Strategic Planning, Operational Optimization, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions, empowering clients with actionable insights for informed decision-making.
